Fluorine-containing FDA-approved small-molecule drugs in 2025: significance, synthetic insights, and therapeutic applications | Synapse
March 15, 2026Open Access
Fluorine-containing FDA-approved small-molecule drugs in 2025: significance, synthetic insights, and therapeutic applications
Key Points
The research aims to explore the significance and applications of fluorine-containing small-molecule drugs approved by the FDA by 2025.
Analyzed the incorporation of fluorine into small-molecule drugs.
Reviewed therapeutic applications and implications for drug design.
Investigated synthetic strategies for fluorine-containing compounds.
Fluorine enhances the metabolic stability and lipophilicity of drugs.
Improved target interactions observed with fluorine incorporation.
The pharmacokinetic profile is significantly affected by fluorine in drug design.
Abstract
Fluorine has been widely incorporated into small-molecule drugs as an effective strategy to modulate metabolic stability, lipophilicity, target interactions, and overall pharmacokinetic profile.